Vion Pharmaceuticals Reaches Midpoint Of Patient Accrual To Cloretazine(R) (VNP40101M) Phase III Trial
14th Nov 2006, 13:31 GMT
Vion Pharmaceuticals, Inc. (Nasdaq: VION) today announced that it had accrued 210 patients to the Phase III trial of its lead anticancer agent Cloretazine(R) (VNP40101M). The trial is evaluating Cloretazine(R)(VNP40101M) in combination with cytarabine for the treatment of relapsed acute myelogenous leukemia (AML). [click link for full article]
Vion Pharmaceuticals Reaches Midpoint Of Patient Accrual To Cloretazine(R) (VNP40101M) Phase III Trial related news:
- Neurogen's obesity drug in phase 1 trial — United Press International - Health Business
- Favrille Announces Interim Analysis of Secondary Endpoint from Pivotal Phase 3 Clinical Trial of FavId Following Rituxan in Follicular B-Cell Non-Hodgkin's Lymphoma — Bio-Technology News from StratCenter.com
- Spectrum Says It Reaches Glaxo Settlement — Pharmaceuticals News from StratCenter.com
- 1st Berlin Releases Research Update Following Callisto Pharmaceutical's Announcement of Initiation of Phase II Trial in Advanced Carcinoid Cancer Patients — Pharmaceuticals News from StratCenter.com
- Favrille drug fails secondary goal — Pharmaceutical Business Review Latest News
- Lilly drug reduces blindness in diabetic patients — Pharmaceutical Business Review Latest News
- Reata brain cancer therapy shows strong activity — Pharmaceutical Business Review Latest News
- Spectrum Pharmaceuticals wird auf dem Kongress der Société Internationale d'Urologie Ergebnisse zu Ozarelix vorstellen — Presseportal.de Finanzen
- Isis Pharma's shares soar on cholesterol-drug Phase II data — MarketWatch.com - Top Stories – Sponsored by: CyberTrader
- - Webcast Alert: Isis Pharmaceuticals Announces Its Analyst/Investor Webcast Presentation — Partnerships/ Joint Ventures News from StratCenter.com
Latest news from Health News from Medical News Today:
- Biotech Industry Welcomes WHO Initiative On Naming Of Biologicals Including Biosimilar Medicines
- Common Cause Of Heart Disease, Diabetes May Be Treatable With Malaria Drug
- Two Nerve Cells In Direct Contact
- Value Of 'Helper' Compound In Treating Some Leukemias
- Internists Take Home Several National Awards At AAMC Annual Meeting
- Most Canadian Med School Grads Lack Basic Surgical Skills
- ACP's Electronic Medical Resource Ranked No. 1 Evidence-based Tool By MLA's South Central Chapter
- University Of Illinois Scientist Helping Processors Keep E. Coli Out Of Meat
- American Thoracic Society Publishes New Statement On Hepatotoxicity Of Antituberculosis Therapy
- Neural Networking Nanotubes